Arcturus Therapeutics ARCT 深 沪
已收盘 12-19 16:00:00 美东时间
6.515
+0.085
+1.32%
华盛通- 最 高7.7586
- 今 开6.44
- 成交量 54.56万股
- 最 低 6.07
- 昨 收 6.43
- 总市值 1.72亿
- 52周最高 24.14
- 市盈率 静 --
- 换手率 2.07%
- 52周最低 5.85
- 委 比 50.20%
- 总股本 2641.90万
- 历史最高 129.71
- 量 比 1.01
- 振 幅 26.26%
- 历史最低 1.10
- 每 手 1
- 风险率 4.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Preview: Arcturus Therapeutics's Earnings
Arcturus Therapeutics (NASDAQ:ARCT) is gearing up to announce its quarterly ear...
11-08 02:05
为了让始祖鸟当网红，安踏把灵魂丢了
来源：源媒汇 作者 | 王言 在被全网捧成“网红”后，始祖鸟还是迎来了营销的反噬。 9月19日，艺术家蔡国强与户外品牌始祖鸟联手，在西藏喜马拉雅山脉江孜...
09-22 17:27
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics has initiated a Phase 2 study to evaluate ZORYVE 0.05% cream in infants 3 months to under 2 years with atopic dermatitis. The four-week study will assess safety and tolerability of once-daily use, addressing limited treatment options for this age group. Atopic dermatitis affects 9.6 million children in the U.S., with up to 60% developing symptoms within the first year.
06-10 12:00
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted 72,000 restricted stock units to 9 new employees under its 2022 Inducement Plan, with a grant date of June 2, 2025. The units vest over four years.
06-06 20:00
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
New data from the INTEGUMENT-OLE study show that ZORYVE cream provides long-term improvement in atopic dermatitis symptoms, with children aged 2–5 achieving disease control for up to 238 days. The cream also demonstrated consistent safety and tolerability.
06-06 12:00
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Arcutis Biotherapeutics' management will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 9-11, 2025. A fireside chat with Arcutis management will take place on June 10, 2025, at 4:00 pm EDT. The webcast can be accessed via the company's website, with a replay available for 180 days post-conference.
05-29 20:00
Americold Realty Trust, Inc. Sets Date for Second Quarter 2025 Earnings Release and Conference Call
Americold Realty Trust will release its Q2 2025 financial results on August 7, 2025, followed by a conference call at 8:00 a.m. ET. A live webcast will be available on the company’s website. Americold is a global leader in temperature-controlled logistics, owning and operating 238 facilities worldwide.
05-22 20:15
